Protocol Calcineurin Inhibitor (CNI) Weaning

Pre-inclusion criteria : * Male or female aged between 18 and 80 years (inclusive), * Having received a deceased donor transplant or living with ABO compatibility, * First renal allograft for at least 4 years and under 10 years, * Presenting a stable renal function : serum creatinine with a variation of ± 25% of the average of the year before inclusion, * Treated with tacrolimus (Prograf®) in combination with MPA (Cellcept® and Myfortic®) + / - steroids (between 5 and 10 mg per day), * Patient has given informed consent, * Patient insured, * Patient (of childbearing age) with effective contraception. Inclusion Criteria: * Glomerular Filtration Rate (GFR), defined by the dosage of cystatin C ≥ 40 ml/min/1, 73m², * Proteinuria ≤ 0,5 g / day, * Patient with serum levels of Tacrolimus between 5 to 10 ng / ml on average during the last 6 months (inclusive). It is accepted that 25% of the assays performed during the last 6 months, serum levels of tacrolimus are outside the limits mentioned above (5-10 ng / ml). They must nevertheless be between 3.5 to 12.5 ng / ml (inclusive). * Patient with serum levels of MPA (Cellcept® and Myfortic®) higher ≥ 30 mg / ml, * No anti-HLA antibodies at the time of inclusion, verified using highly sensitive techniques (Luminex HD), * Lack of histological evidence of cellular or humoral acute or chronic or subclinical rejection on renal graft according to the latest classification of Banff 2009. Exclusion Criteria: * Patients under age 18 or over 80 years, * Transplanted from less than 4 years and over 10 years, * Patients re-transplanted, * Transplantation of several organs, * Patient not treated with tacrolimus as maintenance therapy, * Serum levels of Tacrolimus patient \<5 or \>10 ng / ml, * Serum levels of MPA of the patient \<30 mg / ml, * Patients treated with other immunosuppressive drugs that Tacrolimus (Prograf®), MPA (Cellcept® and Myfortic®) and steroids, * Patient not having a stable graft function at baseline (change in serum creatinine \> 25% of the average of the year before inclusion in the study), with a GFR defined by the dosage of cystatin C \<40 ml/min/1, 73m² at the time of inclusion,- Patients with proteinuria \> 0.5 g at study entry, * Patient with HLA antibodies at study entry, * Patient non-compliant, * Presence of histological evidence of cellular or humoral acute or chronic or subclinical rejection on renal graft according to the latest classification of Banff 2009, * History of lymphoproliferative disorders, * Diagnosis of a malignancy within 5 years before enrollment, * Significantly abnormal hematologic data of a clinical standpoint, as determined by the investigator for hematocrit, hemoglobin, white blood cell count or platelets, * Data significantly abnormal blood biochemistry of a clinical standpoint, as determined by the investigator, * Abuse of significant drug or alcohol at the time of inclusion, determined by the investigator, * Patient positive for antibodies to hepatitis C or hepatitis B surface antigen of hepatitis B (HBsAg) or HIV infection, * Participation in a clinical study within 3 months, * Pregnancy, Breastfeeding.